In the context of an international development project to be conducted during 2015-2020, Gustave Roussy is looking to equip its radiation therapy department with state-of-the-art technologies. In order to develop the best possible care protocols to ensure its patients gain access to the most effective, innovative treatments, Gustave Roussy’s radiation oncology team has selected RayStation® for its treatment planning.
"We are extremely proud to collaborate with such an internationally renowned center as Gustave Roussy," said Johan Löf, CEO of RaySearch. "This represents an important acknowledgement that we, at RaySearch, have succeeded in developing a system that supports and enables cancer care excellence. It is also an incredible boost in our continuous effort to develop best-in-class products to advance cancer treatment. This is an important milestone for our expansion in the French oncology market and we hope that many French cancer patients will benefit from the RayStation® technology."
About RayStation®
RayStation® integrates all RaySearch's advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.
About RaySearch
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch markets the RayStation® treatment planning system to clinics all over the world. In addition, RaySearch's products are distributed through licensing agreements with leading medical technology companies. RaySearch's software is used by over 2,500 clinics in more than 65 countries. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.